Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes
NCT ID: NCT00721656
Last Updated: 2009-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
80 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome
NCT01427816
A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
NCT01692145
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
NCT02092207
A Study of KCT-0809 in Patients With Dry Eye Syndromes
NCT01211951
A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
NCT01890941
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
KLS-0611
KLS-0611
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
KLS-0611
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Insufficiency of lacrimal secretion
* Ocular symptom
Exclusion Criteria
* Punctual plugs or surgery for occlusion of the lacrimal puncta
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kissei Pharmaceutical Co., Ltd.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yasuhiro Omori
Role: STUDY_DIRECTOR
Kissei Pharmaceutical Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Japan
Hokkaido Region, , Japan
Japan
Kansai Region, , Japan
Japan
Kanto Region, , Japan
Japan
Kyushu Region, , Japan
Japan
Shikoku Region, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KLS1201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.